Predicting risk of adverse drug reactions in older adults
Reads0
Chats0
TLDR
Good clinical practice for detecting and predicting ADRs in vulnerable patients includes detailed documentation and regular review of prescribed and over-the-counter medications through standardized medication reconciliation.Abstract:
Adverse drug reactions (ADRs) are common in older adults, with falls, orthostatic hypotension, delirium, renal failure, gastrointestinal and intracranial bleeding being amongst the most common clinical manifestations. ADR risk increases with age-related changes in pharmacokinetics and pharmacodynamics, increasing burden of comorbidity, polypharmacy, inappropriate prescribing and suboptimal monitoring of drugs. ADRs are a preventable cause of harm to patients and an unnecessary waste of healthcare resources. Several ADR risk tools exist but none has sufficient predictive value for clinical practice. Good clinical practice for detecting and predicting ADRs in vulnerable patients includes detailed documentation and regular review of prescribed and over-the-counter medications through standardized medication reconciliation. New medications should be prescribed cautiously with clear therapeutic goals and recognition of the impact a drug can have on multiple organ systems. Prescribers should regularly review medication efficacy and be vigilant for ADRs and their contributory risk factors. Deprescribing should occur at an individual level when drugs are no longer efficacious or beneficial or when safer alternatives exist. Inappropriate prescribing and unnecessary polypharmacy should be minimized. Comprehensive geriatric assessment and the use of explicit prescribing criteria can be useful in this regard.read more
Citations
More filters
Journal ArticleDOI
Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study
Elke L M ter Haar,Sarah E Thomas,Juul M. P. A. van den Reek,M.E. Otero,M. D. Njoo,P.M. Ossenkoppele,Else N. Kop,Sharon Dodemont,J.E.M. Körver,A.L.A. Kuijpers,R. J. Lindhout,R A Tupker,J.M. Mommers,M.A.M. Berends,M.I.A. Koetsier,Marjolein S. de Bruin-Weller,M.B. Visch,W.P. Arnold,P.P.M. van Lümig,M.M. Kleinpenning,Satish F K Lubeek,Elke M G J de Jong +21 more
TL;DR: In this paper , the authors used the Charlson Comorbidity Index (CCI) to measure comorbid disease status, and all adverse events (AEs) that led to treatment discontinuation were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) classification.
Journal ArticleDOI
A single case report on hyponatremia seizure induced by acetylcholinesterase inhibitors
J. Shareef,J. Joseph,K Adithi +2 more
TL;DR: A case on hyponatremia seizure due to the syndrome of inappropriate antidiuretic hormone (SIADH) caused by the acetylcholinesterase inhibitor donepezil and memantine as other likely causes were ruled out by appropriate investigations.
Journal ArticleDOI
Can a practice pharmacist improve prescribing safety and reduce costs in polypharmacy patients? A pilot study of an intervention in an Irish general practice setting
TL;DR: The integration of pharmacists within general practice in Ireland is feasible and is an effective means of improving prescribing safety and implementing deprescribing through medication reviews, as well as highlighting the ease with which a pharmacist could integrate into the general practice setting in Ireland.
Journal ArticleDOI
Medicines‐related harm in the elderly post‐hospital discharge
TL;DR: The risk factors for medicines‐related harm and the recommended strategies to reduce these risks are examined.
Journal ArticleDOI
Antidepressant use and orthostatic hypotension in older adults living with mild-to-moderate Alzheimer disease.
TL;DR: Antidepressant use is often reported as a risk factor for Orthostatic Hypotension (OH), however this relationship has never been explored in those with mild/moderate Alzheimer Disease (AD), who may represent a particularly vulnerable cohort.
References
More filters
Journal ArticleDOI
A method for estimating the probability of adverse drug reactions
Claudio A. Naranjo,Usoa E. Busto,Edward M. Sellers,Paul Sandor,I Ruiz,E A Roberts,E Janecek,Domecq C,David J. Greenblatt +8 more
TL;DR: It was shown that the ADR probability scale has consensual, content, and concurrent validity and may be applicable to postmarketing drug surveillance.
Journal ArticleDOI
Incidence of Adverse Drug Reactions in Hospitalized Patients: A Meta-analysis of Prospective Studies
TL;DR: The incidence of serious and fatal adverse drug reactions in US hospitals was found to be extremely high, and data suggest that ADRs represent an important clinical issue.
Journal ArticleDOI
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Munir Pirmohamed,Sally James,Shaun Meakin,Chris D. Green,A Scott,Tom Walley,Keith Farrar,B. Kevin Park,Alasdair Breckenridge +8 more
TL;DR: The burden ofADRs on the NHS is high, accounting for considerable morbidity, mortality, and extra costs, and measures need to be put into place to reduce the burden of ADRs and thereby further improve the benefit:harm ratio of the drugs.
Journal ArticleDOI
Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts.
Donna M. Fick,James W. Cooper,William E. Wade,Jennifer L. Waller,J. Ross Maclean,Mark H. Beers +5 more
TL;DR: The application of the Beers criteria and other tools for identifying potentially inappropriate medication use will continue to enable providers to plan interventions for decreasing both drug-related costs and overall costs and thus minimize drug- related problems.
Journal ArticleDOI
Adverse drug reactions: definitions, diagnosis, and management.
TL;DR: An adverse drug reaction is an appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of the dosage regimen, or withdrawal of the product.